US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Immunomedics

87.86

0.0000

Volume:- -

Turnover:- -

Market Cap:20.32B

PE:-51.59

High:87.86

Open:87.86

Low:87.86

Close:87.86

52wk High:87.93

52wk Low:8.80

Shares:231.32M

Float Shares:204.79M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7030

EPS(LYR):-1.8448

ROE:-100.04%

ROA:-25.16%

PB:34.25

PE(LYR):-47.63

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Immunomedics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.immunomedics.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMMU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMU\",,,,,undefined,":{"symbol":"IMMU","market":"US","secType":"STK","nameCN":"Immunomedics","latestPrice":87.86,"timestamp":1603396800000,"preClose":87.86,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":204793526,"shares":231320559,"eps":-1.703018,"marketStatus":"Halted","change":0,"latestTime":"10-22 16:00:00 EDT","open":87.86,"high":87.86,"low":87.86,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.703018,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":436942800000,"exchange":"NASDAQ","adjPreClose":87.86,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMU\",,,,,undefined,":{"symbol":"IMMU","floatShares":204793526,"roa":"-25.16%","roe":"-100.04%","lyrEps":-1.844827,"shares":231320559,"dividePrice":0,"high":87.86,"amplitude":0,"preClose":87.86,"low":87.86,"week52Low":8.8,"pbRate":"34.25","week52High":87.93,"institutionHeld":0.9397,"latestPrice":87.86,"eps":-1.703018,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.703018,"open":87.86,"prevYearClose":21.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-10-26","symbol":"IMMU","reason":null,"defaultRemindTime":1603719000000,"announcedDate":"2020-10-15","type":"delisting","dateTimestamp":1603684800000},{"market":"US","date":"2020-08-05","symbol":"IMMU","fiscalQuarterEnding":"2020/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1596600000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2020-05-06","symbol":"IMMU","fiscalQuarterEnding":"2020/03","expectedEps":-0.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1588737600000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2020-02-27","symbol":"IMMU","fiscalQuarterEnding":"2019/12","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1582779600000,"reportTimeType":"post","actualEps":-0.5},{"date":"2019-10-30","symbol":"IMMU","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.4,"defaultRemindTime":1572465600000,"name":null,"time":"Post Market","dateTimestamp":1572408000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMU\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMU","date":"2020-10-23","current":-51.590764,"percent":0,"low":-57.507291,"twenty":-32.594111,"median":-13.007255,"eighty":-7.234548,"high":-3.605351,"avg":-18.336891,"sd":13.018622,"marketCap":20323824313},"quantilePoints":[],"updateTime":1770470840910},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.immunomedics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.638889,"avgChangeRate":0.040069},{"month":2,"riseRate":0.416667,"avgChangeRate":0.00479},{"month":3,"riseRate":0.5,"avgChangeRate":0.031025},{"month":4,"riseRate":0.444444,"avgChangeRate":0.030925},{"month":5,"riseRate":0.567568,"avgChangeRate":0.098275},{"month":6,"riseRate":0.378378,"avgChangeRate":-0.028307},{"month":7,"riseRate":0.459459,"avgChangeRate":-0.022873},{"month":8,"riseRate":0.567568,"avgChangeRate":0.066879},{"month":9,"riseRate":0.513514,"avgChangeRate":-0.00046},{"month":10,"riseRate":0.513514,"avgChangeRate":0.014771},{"month":11,"riseRate":0.527778,"avgChangeRate":0.055185},{"month":12,"riseRate":0.583333,"avgChangeRate":0.172556}],"exchange":"NASDAQ","name":"Immunomedics","nameEN":"Immunomedics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMMU\",market:\"US\",,,undefined,":null}}